Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information
Learn about treatment options, treatment failure, associated adverse effects and more.
Choose from the criteria below to find an activity that fits you best.
|Co-produced by ProCE and the Society of Infectious Diseases Pharmacists (SIDP).|
As the world awaits solutions for the SARS-CoV-2 pandemic, the threat of multidrug resistant bacteria continues to mount. Despite the presence of newer antimicrobials in the armamentarium, clinical and infectious diseases pharmacists experience barriers to their use. This activity will address the latest patterns in gram negative resistance in the United States. Current and emerging treatments, dosing, coverage profiles, and recommended monitoring will provide foundational knowledge on treatment options. Faculty will highlight strategies to navigate formulary decision-making, including guidance on decision support and best practices for restricted use.
The target audience for this activity includes pharmacists. At the completion of this activity, the participant will be able to:
Samuel L. Aitken, PharmD, MPH, BCIDP
Clinical Pharmacy Specialist, Infectious Diseases
Director, PGY2 Infectious Diseases Pharmacy Residency
Division of Pharmacy
The University of Texas MD Anderson Cancer Center
Erin K. McCreary, PharmD, BCPS, BCIDP
Clinical Assistant Professor, University of Pittsburgh School of Medicine
Infectious Diseases Clinical Pharmacist, UPMC
Bruce M. Jones, PharmD, BCPS
Infectious Diseases Clinical Pharmacy Specialist
St. Joseph's/Candler Health System
Release Date: December 7, 2020
Expiration Date: December 31, 2021
This activity is jointly provided by Pro CE, LLC and the Society of Infectious Diseases Pharmacists (SIDP). Pro CE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-20-502-H01-P has been assigned to this home study knowledge-based activity. This activity is approved for 1.5 contact hours (0.15 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of an evaluation and post-test with a score of 70% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Dr. Aitken has received honorarium as an advisory board member for Merck, and a research grant as investigator for Melinta. Dr. McCreary has received honorarium as an advisory board member for Summit, Entasis, Merck, AbbVie, and Shionogi. Dr. Jones has received honorarium as a speaker for Allergan, Tetraphase and Paratek and grant funding as an investigator for Merck.
This activity is supported by an educational grant from Merck.
The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.